Search - tctmd.com

Displaying 121 - 132 of 132

Sort: Relevancy | Date

News Daily News

Late Follow-up of PFO Closure for Stroke Raises Questions for Antiplatelet Duration

Shelley Wood

January 22, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Todd Neale

January 09, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Partner Content

Registration: PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

October 22, 2019

Video

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

October 16, 2019

Video

Evidence for Chronic Aspirin use in CV patients: COMPASS and More

October 16, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

September 28, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

September 27, 2019

Video

Aspirin Use for Primary Secondary Prevention: Critical Appraisal of What We Know and What We Don't

October 17, 2019

Advertisement

Late Follow-up of PFO Closure for Stroke Raises Questions for Antiplatelet Duration

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Registration: PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Evidence for Chronic Aspirin use in CV patients: COMPASS and More

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Aspirin Use for Primary Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content